<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="143017">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02032784</url>
  </required_header>
  <id_info>
    <org_study_id>541923</org_study_id>
    <nct_id>NCT02032784</nct_id>
  </id_info>
  <brief_title>Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding</brief_title>
  <official_title>Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Florida Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Florida Hospital</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our hypothesis is that prophylactic administration of 5 days of Octreotide following EMR or
      ampullectomy in patients with duodenal and ampullary adenomas greater than or equal to 10mm.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion Criteria:

      Duodenal or ampullary adenoma greater than or equal to 10mm. Duodenal or ampullary adenoma
      that is suitable for endoscopic mucosal resection.

      Medically fit for anesthesia, endoscopy, and EMR Able to provide Informed Consent 18 years
      or older, male and female

      Exclusion criteria:

      Duodenal or ampullary adenoma &lt;10mm Duodenal or ampullary adenoma that is not suitable for
      endoscopic mucosal resection Medically unfit for anesthesia, endoscopy, or EMR Unable to
      provide Informed Consent Less than 18 years old Allergy to Octreotide
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Post endoscopic mucosal resection bleeding</measure>
    <time_frame>3 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>clinical evidence of a bleed, including melena, hematochezia, hematemesis</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Adenoma</condition>
  <arm_group>
    <arm_group_label>Octreotide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Octreotide 100mcg subcutaneous every 8 hours for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no octreotide</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no octreotide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>octreotide</intervention_name>
    <description>Octreotide 100mg subcutaneous every 8 hours for 5 days</description>
    <arm_group_label>Octreotide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Duodenal or ampullary adenoma greater than or equal to 10mm Duodenal or ampullary adenoma
        that is suitable for endoscopic mucosal resection Medically fit for anesthesia, endoscopy,
        and EMR Able to provide Informed Consent 18 years or older, male and female

        Exclusion Criteria:

        Duodenal or ampullary adenoma &lt;10mm Duodenal or ampullary adenoma that is not suitable for
        endoscopic mucosal resection Medically unfit for anesthesia, endoscopy, or EMR Unable to
        provide informed consent Less than 18 years old Allergy to Octreotide
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Hawes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Florida Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy L Logue, MSN</last_name>
    <phone>407-303-9736</phone>
    <email>amy.logue@flhosp.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robert Hawes, MD</last_name>
    <phone>407-303-2570</phone>
    <email>robert.hawes.md@flhosp.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amy L Logue, MSN</last_name>
      <phone>407-303-9736</phone>
      <email>amy.logue@flhosp.org</email>
    </contact>
    <contact_backup>
      <last_name>Robert Hawes, MD</last_name>
      <phone>407-303-2570</phone>
      <email>robert.hawes.MD@flhosp.org</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Hawes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 15, 2014</lastchanged_date>
  <firstreceived_date>January 8, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenoma</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Octreotide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
